{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-035271","form_type":"8-K","ticker":"VKTX","cik":"0001607678","company_name":"Viking Therapeutics, Inc.","filed_at":"2022-10-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.390164+00:00","generated_at":"2026-06-23T00:50:36.430622+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Viking Therapeutics Q3 net loss $15.8M ($0.21/sh); cash $155M; three clinical data reads in 2023","bullets":["Net loss of $15.8M ($0.21 per share) vs $13.2M ($0.17) in Q3 2021; nine-month net loss $49.3M ($0.64) vs $42.6M ($0.55).","Cash, cash equivalents and short-term investments $155M, down from $202M at year-end 2021.","VK2809 VOYAGE Phase 2b for NASH/fibrosis enrollment to finish Q4 2022; primary endpoint data 1H 2023.","Phase 1 data for dual GLP-1/GIP agonist VK2735 expected early 2023; Phase 1b VK0214 for X-ALD data in 1H 2023.","R&D expense $12.0M in Q3 vs $10.8M a year ago; G&A $4.2M vs $2.6M."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-035271","json":"https://secwatch.observer/filing/0001564590-22-035271.json","markdown":"https://secwatch.observer/filing/0001564590-22-035271.md","text":"https://secwatch.observer/filing/0001564590-22-035271.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1607678/000156459022035271/0001564590-22-035271-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1607678/000156459022035271/vktx-8k_20221026.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T00:50:36.430622+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}